4-(4-methoxy-phenoxy)-2-methylphenylamine | 620989-09-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-methoxy-phenoxy)-2-methylphenylamine
• 英文别名: 4-(4-Methoxyphenoxy)-2-methylaniline
• CAS: 620989-09-5
• 化学式: C₁₄H₁₅NO₂
• mdl: MFCD08688080
• 分子量: 229.279
• InChiKey: KONLUXDVHBCNRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  368.2±37.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4-(4-methoxy-phenoxy)-2-methylphenylamine 在 亚硝酸特丁酯 、 氢溴酸 、 氰化亚铜 作用下， 以 水 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis

  摘要：

  A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.007
• 作为产物：
  描述：

  4-(4-methoxy-phenoxy)-2-methylnitrobenzene 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 4-(4-methoxy-phenoxy)-2-methylphenylamine
  参考文献：
  名称：

  N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors

  摘要：

  本发明涉及公式1中的N-取代-杂环氧基-芳氧基-2,4,6-三酮金属蛋白酶抑制剂，其中X、A、Y、B、G和R1如规范中所定义，并涉及用于治疗炎症、癌症和其他疾病的药物组合物和方法。

  公开号：

  US20030232849A1

文献信息

• PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1507535A1

  公开（公告）日：2005-02-23
• US6919332B2
  申请人：——

  公开号：US6919332B2

  公开（公告）日：2005-07-19
• [EN] PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEINASE A BASE DE PYRIMIDINE-2, 4, 6-TRIONE
  申请人：PFIZER PROD INC

  公开号：WO2003090751A1

  公开（公告）日：2003-11-06

  The present invention relates to N-substituted-heteroaryloxy-aryloxy-2, 4, 6-trione metalloproteinase inhibitors of the formula (I) wherein X, A, Y, B, G and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders. The compounds are matrix metalloproteinase (MMP) inhibitors.
• Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
  作者：Tsutomu Akama、Stephen J. Baker、Yong-Kang Zhang、Vincent Hernandez、Huchen Zhou、Virginia Sanders、Yvonne Freund、Richard Kimura、Kirk R. Maples、Jacob J. Plattner

  DOI：10.1016/j.bmcl.2009.03.007

  日期：2009.4

  A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis. (C) 2009 Elsevier Ltd. All rights reserved.
• N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
  申请人：Pfizer Inc.

  公开号：US20030232849A1

  公开（公告）日：2003-12-18

  The present invention relates to N-substituted-heteroaryloxy-aryloxy-2,4,6-trione metalloproteinase inhibitors of the formula 1 wherein X, A, Y, B, G, and R 1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.

  本发明涉及公式1中的N-取代-杂环氧基-芳氧基-2,4,6-三酮金属蛋白酶抑制剂，其中X、A、Y、B、G和R1如规范中所定义，并涉及用于治疗炎症、癌症和其他疾病的药物组合物和方法。